

MARKET REPORT



Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additional Details

Publisher : Global Data

Reference : GDHC3633CTIDB

Number of Pages : 1153

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

- Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Renal Cell Carcinoma 30
Aug 04, 2016: Gene expression profile may ID renal cell carcinoma pts unlikely to benefit from nivolumab 30
Jul 08, 2016: Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma 30
Jun 06, 2016: Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity 31
Jun 06, 2016: Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting 32
Jun 05, 2016: Long-Term Survival and Improvement in Quality of Life Observed with Opdivo (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting 33
Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 34
Jun 05, 2016: Tyrogenex Presents Data Informing Phase II and Supporting Potential Efficacy of X-82 with Everolimus in Patients with Solid Tumors at the ASCO Annual Meeting 2016 35
Jun 05, 2016: BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting 36
May 26, 2016: AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma 37
May 23, 2016: Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 37
May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 38
Clinical Trial Profile Snapshots 41
Appendix 1150
Abbreviations 1150
Definitions 1150
Research Methodology 1151
Secondary Research 1151
About GlobalData 1152
Contact Us 1152
Disclaimer 1152
Source 1153

List Of Tables in Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

List of Tables

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016*	7
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*	8
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*	9
Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*	10
Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*	11
Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016*	12
Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*	13
Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*	14
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016*	15
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*	16
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*	17
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016*	18
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*	19
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*	20
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016*	21
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016*	22
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*	23
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*	24
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015	25
Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*	26
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*	27
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*	28
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*	29

List Of Figures, Charts and Diagrams in Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

List of Figures

- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
- Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
- Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
- Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
- Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
- Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
- Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 15
- Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
- Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
- Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 18
- Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
- Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
- Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
- Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
- Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
- Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
- Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
- Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
- Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
- GlobalData Methodology 1151

How to Buy...

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27256>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.